Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

AstraZeneca

Status: Completed

Conditions: Type II Diabetes Mellitus

Study type: Observational

Funder types: Industry

Identifiers

NCT03084965

D1690R00022

Details and patient eligibility

About

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.

Enrollment: 1,987 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Outpatient equal to or more than 20 years of age.
2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third line oral anti-diabetic therapy, either as add-on or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin.
3. Completed follow-up of at least 6 months regardless of continuation on dapagliflozin therapy.
4. Will provide completed and signed written informed consents.

Exclusion criteria

1. Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to Baseline.
2. Subjects with Type 1 diabetes.
3. Treatment with other investigational drugs concurrently during the retrospective data collection period.